These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 37373348)

  • 1. Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis.
    Mendoza-Torreblanca JG; Cárdenas-Rodríguez N; Carro-Rodríguez J; Contreras-García IJ; Garciadiego-Cázares D; Ortega-Cuellar D; Martínez-López V; Alfaro-Rodríguez A; Evia-Ramírez AN; Ignacio-Mejía I; Vargas-Hernández MA; Bandala C
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis.
    Novella-Maestre E; Carda C; Noguera I; Ruiz-Saurí A; García-Velasco JA; Simón C; Pellicer A
    Hum Reprod; 2009 May; 24(5):1025-35. PubMed ID: 19189995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis.
    Delgado-Rosas F; Gómez R; Ferrero H; Gaytan F; Garcia-Velasco J; Simón C; Pellicer A
    Reproduction; 2011 Nov; 142(5):745-55. PubMed ID: 21862695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic phytochemicals and medicinal herbs.
    Jeong SJ; Koh W; Lee EO; Lee HJ; Lee HJ; Bae H; Lü J; Kim SH
    Phytother Res; 2011 Jan; 25(1):1-10. PubMed ID: 20564543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis.
    Chakroborty D; Sarkar C; Mitra RB; Banerjee S; Dasgupta PS; Basu S
    Clin Cancer Res; 2004 Jul; 10(13):4349-56. PubMed ID: 15240521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
    Shibuya M
    J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
    J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Anti-VEGF/VEGFR Agents on Animal Models of Endometriosis: A Systematic Review and Meta-Analysis.
    Liu S; Xin X; Hua T; Shi R; Chi S; Jin Z; Wang H
    PLoS One; 2016; 11(11):e0166658. PubMed ID: 27855197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biflavonoid amentoflavone inhibits neovascularization preventing the activity of proangiogenic vascular endothelial growth factors.
    Tarallo V; Lepore L; Marcellini M; Dal Piaz F; Tudisco L; Ponticelli S; Lund FW; Roepstorff P; Orlandi A; Pisano C; De Tommasi N; De Falco S
    J Biol Chem; 2011 Jun; 286(22):19641-51. PubMed ID: 21471210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
    Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
    Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Inhibitory Effect of Selected D
    Kasica N; Święch A; Saładziak K; Mackiewicz J; Osęka M
    Cells; 2022 Apr; 11(7):. PubMed ID: 35406766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis.
    Ricci AG; Olivares CN; Bilotas MA; Meresman GF; Barañao RI
    Reprod Sci; 2011 Jul; 18(7):614-22. PubMed ID: 21266664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.
    Chung TW; Kim SJ; Choi HJ; Kwak CH; Song KH; Suh SJ; Kim KJ; Ha KT; Park YG; Chang YC; Chang HW; Lee YC; Kim CH
    J Mol Med (Berl); 2013 Feb; 91(2):271-82. PubMed ID: 22935775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring quercetin and luteolin derivatives as antiangiogenic agents.
    Ravishankar D; Watson KA; Boateng SY; Green RJ; Greco F; Osborn HM
    Eur J Med Chem; 2015 Jun; 97():259-74. PubMed ID: 25984842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.